155 439

Cited 6 times in

HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer

DC Field Value Language
dc.contributor.author김명희-
dc.contributor.author김유리-
dc.contributor.author오지훈-
dc.date.accessioned2021-09-29T01:07:30Z-
dc.date.available2021-09-29T01:07:30Z-
dc.date.issued2021-06-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184208-
dc.description.abstractTamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition of tamoxifen resistance. In this study, we identified HOXA5, a member of the HOX gene family, as a marker of tamoxifen resistance. Using ChIP assay, we found that HOXA5 expression was significantly overexpressed in tamoxifen-resistant MCF7 (TAMR) breast cancer cells because of reduced H3K27me3 binding. HOXA5 upregulation resulted in activation of the PI3K/AKT signaling cascade, which in turn, led to p53 and p21 reduction, ultimately making the TAMR cells less apoptotic. Furthermore, elevated HOXA5 expression resulted in breast cancer cells acquiring more mesenchymal-like and stem cell traits associated with aggressive breast cancer phenotypes. In conclusion, our results delineate a mechanism by which HOXA5 promotes tumorigenesis, cancer progression, and tamoxifen resistance in breast cancer cells.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherIvyspring International Publisher-
dc.relation.isPartOfJOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleHOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Anatomy (해부학교실)-
dc.contributor.googleauthorClara Yuri Kim-
dc.contributor.googleauthorYu Cheon Kim-
dc.contributor.googleauthorJi Hoon Oh-
dc.contributor.googleauthorMyoung Hee Kim-
dc.identifier.doi10.7150/jca.59740-
dc.contributor.localIdA00432-
dc.contributor.localIdA05900-
dc.contributor.localIdA02400-
dc.relation.journalcodeJ01281-
dc.identifier.eissn1837-9664-
dc.identifier.pmid34149926-
dc.subject.keywordAKT-
dc.subject.keywordHOXA5-
dc.subject.keywordbreast cancer-
dc.subject.keywordp53-
dc.subject.keywordtamoxifen resistance-
dc.contributor.alternativeNameKim, Myoung Hee-
dc.contributor.affiliatedAuthor김명희-
dc.contributor.affiliatedAuthor김유리-
dc.contributor.affiliatedAuthor오지훈-
dc.citation.volume12-
dc.citation.number15-
dc.citation.startPage4626-
dc.citation.endPage4637-
dc.identifier.bibliographicCitationJOURNAL OF CANCER, Vol.12(15) : 4626-4637, 2021-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anatomy (해부학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.